American Association for Cancer Research (AACR) Archives - Sanford Burnham Prebys
Institute News

Erkki Ruoslahti named a Fellow of the AACR Academy

AuthorMiles Martin
Date

April 14, 2023

The American Association for Cancer Research (AACR) has elected Distinguished Professor Emeritus Erkki Ruoslahti, MD PhD, to its 2023 class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer.

Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

All Fellows are nominated and elected through an annual, multi-step peer review process that involves a rigorous assessment of each candidate’s scientific accomplishments in cancer research and cancer-related sciences. Only individuals whose work has had a significant and enduring impact on cancer research are considered for election and induction into the AACR Academy.

“We are proud to announce the election of 23 new Fellows of the AACR Academy. These individuals from across the world have all made significant and groundbreaking contributions to cancer research,” said Margaret Foti, Ph.D, M.D (hc), chief executive officer of the AACR. “The 2023 class of Fellows includes pioneers from numerous scientific disciplines who have collectively shaped our understanding and treatment of cancer. We are deeply honored to have them join our 289 existing Fellows and look forward to celebrating their extraordinary scientific achievements at our upcoming Annual Meeting.”

Erkki Ruoslahti, MD, PhD

Ruoslahti was elected for his paramount discoveries involving the mechanisms of cellular adhesion; for the co-discovery of fibronectin, the discovery of the fibronectin RGD cell attachment sequence, homing peptides, and tumor-penetrating peptides; and for the development of therapeutics for vascular thrombosis and cancer.

Ruoslahti joined Sanford Burnham Prebys in 1979 and served as its President from 1989-2002. In 2022, Ruoslahti announced as one of three winners of the Albert Lasker Basic Medical Research Award for his work on cellular adhesion. Ruoslahti’s other honors include the Japan Prize, the Gairdner Foundation International Award, the G.H.A. Clowes Memorial Award, and the Robert J. and Claire Pasarow Foundation Medical Research Award. He is a Knight of the Order of the White Rose of Finland, a Commander of the Order of the Lion of Finland, and one of the most cited scientists in the world.

This post was adapted from a press release issued by the American Association for Cancer Research.

Institute News

AACR selects Sanford Burnham Prebys scientist as NextGen Star

AuthorMonica May
Date

April 4, 2019

The American Association for Cancer Research (AACR) has named Cosimo Commisso, PhD, assistant professor in Sanford Burnham Prebys’ NCI-designated Cancer Center, as a NextGen Star. 

The program strives to increase the visibility of early career scientists at the organization’s annual meeting—one of the year’s largest gatherings of cancer researchers—and to support their professional development and advancement. The 2019 AACR Annual Meeting was held from March 29 to April 3 in Atlanta and attracted more than  21,000 scientists and clinicians. 

As a NextGen star, Commisso was featured on AACR’s website and was invited to give a presentation during a special “NextGen Star” session. He also presented in a session titled, “Features and Functions of the Pancreatic Tumor Microenvironment.” Both talks were well attended.

Commisso’s presentations focused on pancreatic cancer, a deadly and difficult-to-detect tumor. Less than 10 percent of people who are diagnosed with pancreatic cancer are alive five years later. More than 56,000 Americans are expected to be diagnosed with pancreatic cancer in 2019 and its incidence is on the rise. Pancreatic cancer is on track to become the second leading cause of cancer-related death in the U.S. next year, according to the Pancreatic Cancer Action Network. New studies have linked military service to an increased risk of pancreatic cancer, perhaps due to exposure to herbicides such as Agent Orange.

Commisso is working to halt pancreatic cancer growth by studying the way cells internalize nutrients, called macropinocytosis. In this process, cells extend their membranes to capture nutrients in their surrounding environment—similar to how humans swallow a pill by encasing it in water. 

“We’ve discovered that pancreatic tumors that have a mutation in the RAS gene—which occurs in almost all cases—fuel their growth by kicking macropinocytosis into overdrive,” says Commisso. “By halting macropinocytosis, essentially cutting off the cancer cells’ fuel supply, we hope we can develop effective, much-needed treatments for pancreatic cancer.”

In his NextGen Star presentation, Commisso detailed how macropinocytosis is dialed up or down depending on nutrient availability. Studies performed by Szu-Wei Lee, PhD, a postdoctoral fellow in the Commisso laboratory, indicate that RAS-mutated pancreatic tumors use two forms of macropinocytosis—one that is “always on” (constitutive) and another that is nutrient dependent.

“Uncovering the molecular differences between these two pathways could yield personalized targets that selectively target pancreatic cancer cells,” says Commisso. “In addition to pancreatic tumors, new evidence shows that lung, prostate and bladder cancers highjack macropinocytosis to keep growing. This means our work in pancreatic cancer may also lead to new treatments for these other tumor types.”

Watch Dr. Commisso explain his lab’s focus

View the full list of the NextGen stars 

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries below.

Institute News

High levels of protein p62 predict liver cancer recurrence

AuthorJessica Moore
Date

May 19, 2016

CANCER METABOLISM AND SIGNALING NETWORKS PROGRAM

New research from SBP and UC San Diego shows that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival. p62 was also found to be required for liver cancer to form in mice. Continue reading “High levels of protein p62 predict liver cancer recurrence”

Institute News

SBP presents at American Association for Cancer Research’s annual meeting

AuthorKristen Cusato
Date

May 10, 2016

Deputy Director of the NCI-designated Cancer Center, Jorge Moscat, PhD, and Cosimo Commisso, PhD, assistant professor in the Center, presented at the AACR conference in New Orleans.

Moscat presented at the session titled “Metabolic Interplay between Tumor and Microenvironment.”

“Cancer cells have to adapt their metabolism to survive nutrient deprivation and several stress conditions in their tumor microenvironment. For this they put in motion a process called autophagy whereby they get rid of toxic intracellular molecules and organelles and generate nutrients that allow them to survive,” said Moscat.

“Central to this process is a protein called p62 that was discovered in collaboration with my SBP colleague Maria Diaz-Meco. This protein is upregulated in, for example, liver cancer, whose mortality has increased dramatically over the last 10 years, in marked contrast to many other neoplasias that have shown a significant decrease in mortality.

“We presented new compelling data from human patients, mouse models and cell culture studies demonstrating that inactivation of p62 in cancer liver cells dramatically reduced the incidence and aggressiveness of hepatocellular carcinoma. Therefore, p62 is a novel and potentially actionable therapeutic target in liver cancer,” added Moscat.

Moscat said he was impressed at AACR by the number and quality of research studies linking the possibility of treating patients by a combined strategy of targeting cancer metabolism and the immunological tumor microenvironment.

He also spoke to ecancer.tv, an online provider of oncology news, about his research. Watch the video here.

Moscat is co-chair of a symposium on related research in cancer metabolism to that will be held June 22-23 at SBP’s La Jolla campus.

Commisso’s presentation was featured in a special session on pancreatic cancer that aimed to stimulate opportunities for collaboration between Pancreatic Cancer Action Network-AACR grantees and others in the field.

“The research that I presented was focused on a novel drug target in pancreatic cancer discovered recently by my lab,” said Commisso.

“We have found that an ion transporter that regulates pH homeostasis is critical to pancreatic cancer cell survival. This previously uncharacterized transporter plays a role in maintaining amino acid supply in tumor cells that harbor a mutation in the oncogene known as Ras, which is mutated in >90% of pancreatic tumors.

“Our future work is focused on exploring the role of this transporter in preclinical models and developing new approaches to inhibit this druggable target,” added Commisso.

He called the AACR meeting “a remarkable opportunity for cancer researchers to come together and share their exciting discoveries.”  Dr. Commisso also said it was a good opportunity to connect with colleagues and friends to develop and nurture scientific collaborations, to create, progress and build.

Commisso will also present at the 2016 PancWest Symposium in September at the Moores Cancer Center at UCSD.

Institute News

Sanford-Burnham presents at AACR April 19-22

Authorsgammon
Date

April 21, 2015

 

The American Association of Cancer Research (AACR) Annual Meeting, held April 18-22 in Philadelphia, will attract approximately 18,000 attendees from around the world. They are coming to hear from an outstanding roster of speakers, hundreds of live talks, and more than 6,000 proffered papers from scientists and clinicians around the world. This year’s theme, “Brining Cancer Discoveries to patients,” highlights the need to link laboratory discoveries to treatments for the purpose of finding cancer cures. Continue reading “Sanford-Burnham presents at AACR April 19-22”

Institute News

National Academy of Inventors names two Sanford-Burnham researchers as Charter Fellows

Authorsgammon
Date

December 16, 2014

Two Sanford-Burnham professors have been named Charter Fellows of the National Academy of Inventors (NAI): Erkki Ruoslahti, MD, PhD, distinguished professor and former president of Sanford-Burnham, and Kristiina Vuori, MD, Ph.D., current president of the Institute. Ruoslahti and Vuori are now part of a group of 414 NAI Fellows from more than 150 prestigious research universities, government, and nonprofit research institutions. Continue reading “National Academy of Inventors names two Sanford-Burnham researchers as Charter Fellows”

Institute News

The switch that promotes kidney cancer progression and metastasis

Authorsgammon
Date

December 12, 2014

Kidney cancer is the sixth most common cancer in adults in the United States. Clear-cell kidney cancer, or clear-cell renal cell carcinoma (CRCC)—the cells appear pale and clear under a microscope—accounts for seven out of 10 people with kidney cancer, and is the most aggressive form of the disease. Because kidney cancer does not cause symptoms until the tumor has already grown, and is very difficult to detect in a routine physical examination, approximately 25 to 30 percent of patients aren’t diagnosed until the disease is metastatic. Unfortunately, metastatic clear-cell kidney cancer is currently incurable. Continue reading “The switch that promotes kidney cancer progression and metastasis”

Institute News

From the American Association for Cancer Research—what you should know about cancer in 2014

Authorsgammon
Date

September 16, 2014

The American Association for Cancer Research (AACR) has released its 2014 Progress Report. This is the fourth report that chronicles the progress that has been made against cancer, describes how the NIH and NCI are transforming lives by funding research, and highlights new approaches to achieve better outcomes for patients. Continue reading “From the American Association for Cancer Research—what you should know about cancer in 2014”